Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Director departure
Inv. presentation
Quarterly results
Appointed director
CC transcript
OSI PHARMACEUTICALS INC (OSIP) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/22/2010 8-K Quarterly results
Docs: "OSI Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results - Total Revenues Increased 14% Year over Year to $107 Million -",
"Script for OSI's First Quarter 2010 Earnings Conference Call held on April 22, 2010",
"FDA APPROVES TARCEVA AS A MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER"
10/21/2009 8-K Form 8-K - Current report
07/22/2009 8-K Quarterly results
Docs: "OSI Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results - Tarceva Global Net Sales of $290 million -",
"NEW DATA FROM PHASE III SATURN STUDY SHOWED TARCEVA IMPROVED OVERALL SURVIVAL WHEN USED IMMEDIATELY AFTER INITIAL CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON- SMALL CELL LUNG CANCER",
"OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration"
04/29/2009 8-K Form 8-K -- Current report
02/19/2009 8-K Quarterly results
Docs: "OSI Pharmaceuticals, Inc. Announces Year End 2008 Financial Results - Reports Non-GAAP Earnings of $2.14 Per Share from Continuing Operations, Excluding $337 Million Non-Cash Gain - - GAAP Earnings from Continuing Operations are $7.19 Per Share Inclusive of Non-Cash Gain - - Total Revenues of $379 Million Up 11% Over 2007 -"
10/23/2008 8-K Quarterly results
Docs: "OSI Pharmaceuticals Announces Third Quarter 2008 Financial Results — Reports Earnings of $0.56 Per Share From Continuing Operations — — Tarceva Global Net Sales of $279 Million Up 23% Over The Third Quarter of 2007",
"Textual representation of certain portions of the webcast conference call held on October 22, 2008"
07/25/2008 8-K Quarterly results
Docs: "OSI Pharmaceuticals Announces Second Quarter 2008 Financial Results —Reports Earnings of $0.61 Per Share From Continuing Operations —Tarceva Global Net Sales of $292 Million, Up 37% Over the Second Quarter of 2007",
"Textual representation of certain portions of the webcast conference call held on July 23, 2008"
05/08/2008 8-K Quarterly results
Docs: "OSI Pharmaceuticals Announces First Quarter 2008 Financial Results - Reports Earnings of $0.52 Per Share from Continuing Operations - - Net Income From Continuing Operations Up 61% Over First Quarter 2007 - - Tarceva Related Revenue Up 39% Over First Quarter 2007-",
"Textual representation of certain portions of the webcast conference call held on May 6, 2008"
02/26/2008 8-K Quarterly results
Docs: "OSI Pharmaceuticals Announces Year End 2007 Financial Results —Reports Earnings of $1.70 Per Share From Continuing Operations —Tarceva Global Net Sales of $886 Million Up 36% Over 2006",
"Textual representation of certain portions of the webcast conference call held on February 21, 2008"
10/29/2007 8-K Quarterly results
Docs: "OSI Pharmaceuticals Announces Third Quarter 2007 Financial Results - Reports Earnings of $0.59 Per Share From Continuing Operations — - - Tarceva Global Net Sales of $226 Million Up 32% Over The Third Quarter of 2006",
"Textual representation of certain portions of the webcast conference call held on October 25, 2007",
"OSI PHARMACEUTICALS SUMMARIZES DATA PRESENTED ON OSI-906 AT THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS",
"TARCEVA ® EARNS APPROVAL FOR LUNG CANCER PATIENTS IN JAPAN"
07/31/2007 8-K Quarterly results
Docs: "OSI Pharmaceuticals Announces Second Quarter 2007 Financial Results - Reports Earnings of $0.48 Per Share From Continuing Operations — -",
"OSI Pharmaceuticals Announces Agreement to Divest Anti-Platelet Derived Growth Factor Program - First Transaction in On-going Eye Business Divesture Process -",
"Textual representation of certain portions of the webcast conference call held on July 30, 2007"
05/02/2007 8-K Quarterly results
Docs: "OSI Pharmaceuticals Announces First Quarter 2007 Financial Results - Reports Earnings of $0.33 Per Share from Continuing Operations — - Total Revenue Up 31% Over First Quarter 2006 -",
"Textual representation of certain portions of the webcast conference call held on April 26, 2007"
02/23/2007 8-K Quarterly results
Docs: "OSI Pharmaceuticals Announces Year End 2006 Financial Results",
"Textual representation of certain portions of the webcast conference call held on February 21, 2007"
11/08/2006 8-K Quarterly results
Docs: "OSI Pharmaceuticals Announces Third Quarter 2006 Financial Results — Company Announces it Plans to Exit Eye Disease Business",
"Textual representation of certain portions of the webcast conference call held on November 7, 2006"
08/09/2006 8-K Quarterly results
Docs: "OSI Pharmaceuticals Announces Second Quarter 2006 Financial Results",
"OSI PHARMACEUTICALS ANNOUNCES THAT ROCHE HAS RECEIVED NEGATIVE CHMP OPINION IN EUROPEAN UNION ON TARCEVA ® IN PANCREATIC CANCER",
"Textual representation of certain portions of the webcast conference call held on August 8, 2006"
05/12/2006 8-K Quarterly results
Docs: "OSI Pharmaceuticals Announces First Quarter 2006 Financial Results",
"Textual representation of certain portions of the webcast conference call held on May 9, 2006"
03/08/2006 8-K Quarterly results
Docs: "OSI PHARMACEUTICALS ANNOUNCES YEAR END 2005 FINANCIAL RESULTS"
11/03/2005 8-K Quarterly results
Docs: "OSI PHARMACEUTICALS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS",
"Textual representation of certain portions of the webcast conference call held on November 1, 2005"
08/02/2005 8-K Quarterly results
Docs: "OSI PHARMACEUTICALS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS; COMPANY REPORTS GAAP AND NON-GAAP LOSS NARROWS FOR SECOND QUARTER COMPARED TO COMPARABLE QUARTER A YEAR AGO",
"PIVOTAL PHASE III TARCEVA STUDY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE SHOWED SURVIVAL IMPROVEMENT IN ADVANCED NON-SMALL CELL LUNG CANCER",
"RESULTS ASSESSING ROLE OF EGFR EXPRESSION, AMPLIFICATION, AND MUTATION PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE",
"OSI PHARMACEUTICALS ANNOUNCES TARCEVA GRANTED APPROVAL IN CANADA FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER",
"OSI PHARMACEUTICALS ADVANCES DIABETES PROGRAM; GLYCOGEN PHOSPHORYLASE INHIBITOR CANDIDATE PSN357 ADVANCES TO PHASE I CLINICAL TRIAL",
"REPRESENTATION OF CERTAIN PORTIONS OF THE WEBCAST CONFERENCE CALL HELD ON JULY 28, 2005"
05/06/2005 8-K Quarterly results
Docs: "OSI PHARMACEUTICALS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS",
"OSI PHARMACEUTICALS AND GENENTECH ANNOUNCE FILING OF A SUPPLEMENTAL NEW DRUG APPLICATION TO THE FDA FOR TARCEVA(TM) IN PANCREATIC CANCER",
"OSI PHARMACEUTICALS, INC. MAY 3, 2005 8:00 A.M. EST"
12/02/2004 8-K Quarterly results
Docs: "OSI PHARMACEUTICALS ANNOUNCES FISCAL 2004 FINANCIAL RESULTS"
08/11/2004 8-K Quarterly results
Docs: "OSI PHARMACEUTICALS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS"
05/13/2004 8-K Quarterly results
Docs: "OSI PHARMACEUTICALS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS - CONFERENCE CALL AND WEBCAST TO FOLLOW -"
01/30/2004 8-K Quarterly results
Docs: "OSI - INVESTOR INFORMATION"
11/20/2003 8-K Quarterly results
08/12/2003 8-K Quarterly results
Docs: "OSI PHARMACEUTICALS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy